Senzer, a privately-held British firm, has announced its intention to launch its portfolio of inhaled cannabinoid therapies in the UK.
First to launch in the UK will be Cannafen (cannabidiol), followed by Candex (dronabinol) in early 2019. Both drugs are adminstered via Senzer's unique inhaler system.
"Our delivery technology is a first of its kind — a respiratory delivery system that uses a breath-operated valve technology and delivers pharmaceutical grade cannabinoids rapidly into the bloodstream," said Alex Hearn, chief executive of Senzer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze